High dose of botulinum toxin type-A (BTX/A): Safety and efficacy in patients with cerebral palsy

Journal of Pediatric Neurology

Volumn 2, Issue 2, 2004, Pages 91-96

  Awaad, Yasser ^a   Tayem, Hassan ^a   Munoz, Sharon ^a   Thomas, Ronald ^a   Soliman, Sherif ^a   Michon, Anne Marie ^a   Minarik, Sarah ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Oakwood Healthcare Inc   (United States)

Author keywords

Botulinum toxin; Cerebral palsy; Safety and efficacy; Spasticity

Indexed keywords

EID: 85013596923     PISSN: 13042580     EISSN: 13050613     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Koman LA, Mooney JF 3rd, Smith B, Goodman A, Mulvaney T. Management cerebral palsy with botulinum-A toxin: preliminary investigation. J Pediatr Orthop 1993; 13: 489-495.
2. Steinbok P, Reiner AM, Beauchamp R, Armstrong RW, Cochrane DD, Kestle J. A randomized clinical trial to compare selective posterior rhizotomy plus physiotherapy with physiotherapy alone in children with spastic diplegic cerebral palsy. Dev Med Child Neurol 1997; 39: 178-184.
3. Koman LA, Mooney JF 3rd, Smith B. Neuromuscular blockade in the management of cerebral palsy. J Child Neurol 1996; 11 Suppl 1: S23-S28.
4. Albright AL. Intrathecal baclofen in cerebral palsy movement disorders. J Child Neurol 1996; 11 Suppl 1: S29-S35.
5. Cai S, Sarkar HK, Singh BR. Enhancement of the endopeptidase activity of botulinum neurotoxin by its associated protein and dithiothreitol. Biochemistry 1999; 38: 6903-6910.
6. Borodic GE, Pierce LB, Ferrante R. Therapeutic botulinum toxin: histologic effects and diffusion properties botulinum and tetanus neurotoxins. In: DasGupta BR (ed). Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects. New York: Plenum press, 1993, pp 623-645.
7. Cosgrove AP, Corry IS, Grahm HK. Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol 1994; 36: 386-396.
8. Denislic M, Meh D. Botulinum toxin in the treatment of cerebral palsy. Neuropediatrics 1995; 26: 249-252.
9. Koman LA, Mooney JF 3rd, Smith BP, Goodman A, Mulvaney T. Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial. J Pediatr Orthop 1994; 14: 299-303.
10. Gooch JL, Sandell TV. Botulinum toxin for spasticity in children with cerebral palsy. Arch Phys Med Rehabil 1996; 77: 508-511.
11. Calderon-Gonzalez R, Calderon-Sepulveda R, Rincon-Reyes M, Garcia-Ramirez J, Mino-Arango E. Botulinum toxin A in management of cerebral palsy. Pediatr Neurol 1994; 10: 284-288.
12. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987; 67: 206-207.
13. Mall V, Kirschner J, Linder M, et al. Botulinum toxin A in children with cerebral palsy: evaluation of therapy using the Pediatric Evaluation of Disability Inventory (PEDI). J Pediatr Neurol 2003; 1: 29-34.
14. Bakheit AM, Ward CD, McLellan DL. Generalised botulism-like syndrome after intramuscular injections of botulinum toxin type A: a report of two cases. J Neurol Neurosurg Psychiatry 1997; 62: 198.